SecBot SecBot
8-K ·Filed Feb 26, 2026

NUVL

Nuvalent, Inc.
BULLISH
Impact 7/10
Horizonmonths Processed8mo ago SEC0001193125-26-073304
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The FDA acceptance of the NDA for zidesamtinib with a clear PDUFA date creates a near-term catalyst for the stock. The strong cash position supports ongoing development and potential commercialization efforts. Traders should monitor upcoming clinical trial progress and regulatory interactions.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$103.93
T+0 close · Feb 26, 2026 · via day close
Latest settled
−2.59%
T+60 · $101.24
Vs SPY
−10.34%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Feb 26 $103.93entry
  2. T+1 · 9mo ago −1.91%α −1.45% · $101.95
  3. T+5 · 9mo ago −3.66%α −2.53% · $100.13
  4. T+20 · 8mo ago −5.65%α +0.75% · $98.06
  5. T+60 · 6mo ago −2.59%α −10.34% · $101.24
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Nuvalent reported its 2025 financial results, highlighted a strong cash position of $1.4 billion with runway into 2029, and provided updates on its drug development pipeline. Key milestones include FDA acceptance of the NDA for zidesamtinib with a PDUFA date of September 18, 2026, and plans for neladalkib NDA submission in the first half of 2026. The company also completed a $500 million public offering in November 2025.

Key Financial Metrics

EPS
$-5.85

Key Facts

  • Cash, cash equivalents and marketable securities were $1.4 billion as of December 31, 2025
  • FDA accepted NDA for zidesamtinib with PDUFA target action date of September 18, 2026
  • Completed $500 million public offering of common stock in November 2025
  • R&D expenses were $307.0 million for full year 2025
  • Net loss was $425.4 million for full year 2025

Financial Impact

Strong financial position with $1.4 billion in cash and marketable securities, providing runway into 2029

cashR&D expensesnet loss

Risk Factors

  • Clinical trial results may not meet expectations
  • FDA may not approve zidesamtinib or neladalkib on the expected timeline
  • High R&D expenses will continue to generate net losses

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-073304
Document: nuvl-20260226.htm0001193125-26-073304
Document: 0001193125-26-073304-index-headers.html0001193125-26-073304
Document: 0001193125-26-073304-index.html0001193125-26-073304
Document: 0001193125-26-073304.txt0001193125-26-073304

US Market Status

Market Closed · Opens in 9h 6m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Feb 26, 2026